Showing results (2201-2210 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|November 9, 2019
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalXavier G L V Pouwels, Svenja Petersohn, Vanesa Huertas Carrera, et al.
Pharmacoeconomics|December 13, 2019
Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic SyndromeMichael Ryan, Bonnie M K Donato, William Irish, et al.
Pharmacoeconomics|December 17, 2019
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net BenefitChristopher McCabe, Mike Paulden, Isaac Awotwe, et al.
Pharmacoeconomics|June 25, 2021
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement FrameworkLuca M M Janssen, Ruben M W A Drost, Aggie T G Paulus, et al.
Pharmacoeconomics|June 21, 2021
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)Michael J Zoratti, Kelvin K W Chan, Don Husereau, et al.
Pharmacoeconomics|February 3, 2018
A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. CinacalcetBjörn Stollenwerk, Sergio Iannazzo, Ron Akehurst, et al.
Pharmacoeconomics|December 7, 2018
Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and NeckBrent A Metfessel, Michelle D Mentel, Amy Phanel, et al.
Pharmacoeconomics|December 15, 2018
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology AppraisalFrederick W Thielen, Nasuh C Büyükkaramikli, Rob Riemsma, et al.
Pharmacoeconomics|December 23, 2018
Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United StatesHolly Guy, Vicki Laskier, Mark Fisher, et al.
Pharmacoeconomics|February 26, 2018
Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology AppraisalIrina A Tikhonova, Tracey Jones-Hughes, James Dunham, et al.
Pageof 336